Gastrointestinal Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY25269
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.
Study InformationSTUDY25534
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
To compare health-related quality of life (HRQOL) by treatment arm at 8 weeks after randomization, measured using the Functional Assessment of Cancer Therapy Gastric (FACT-Ga) Trial Outcome Index.
Study InformationSTUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.
Study InformationSTUDY26953
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
To evaluate whether dose-escalated RT improves 3-year overall survival (OS) compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.
Study Information